The PAN Foundation, a leading charitable assistance foundation and healthcare advocacy organization, today announced new findings that highlight the formulary coverage and access shifts facing patients enrolled in standalone prescription drug plans (PDPs) and low-income subsidy (LIS) benchmark plans, including changes in premiums and plan offerings.
The analysis, conducted by Avalere and sponsored by PAN as part of its Center for Patient Research, found that 12 percent of PDPs offered in 2023 were not available in 2024, impacting about 400,000 enrollees. In addition, 31 percent of 2023 PDPs lost LIS benchmark status in 2024, representing 3.2 million LIS benchmark plan enrollees—causing them to have to either choose a new plan or pay a premium in 2024. Read More >
